# US 2020/0390723 A1 · Treatment of fibrosis with inositol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390723 A1
- Document ID: US20200390723A1
- Status: Published application
- Kind: A1
- Application number: 16/955,220
- Filed: 2018-12-20
- Published: 2020-12-17
- Earliest claimed: 2017-12-22
- Assignees: Lo.Li. Pharma International S.R.L.
- Applicants: Lo.Li. Pharma International S.R.L.
- Inventors: Vittorio UNFER
- Web page: https://patentgrep.com/patent/US20200390723A1

## CPC

- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the medical use of inositol for the treatment of reactive muscle fibrosis, e.g. reactive cardiac fibrosis, in a subject. The present invention further relates to methods of treating reactive muscle fibrosis, e.g. reactive cardiac fibrosis by administering inositol to a subject.

## Claims

### Claim 1

A method of treating or preventing reactive muscle fibrosis in a subject, comprising administering an effective amount of inositol to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said reactive muscle fibrosis is cardiac fibrosis.

### Claim 3 (depends on 2)

The method of claim 2, wherein said cardiac fibrosis is interstitial cardiac fibrosis, perivascular cardiac fibrosis or both interstitial and perivascular cardiac fibrosis.

### Claim 4 (depends on 1)

The method of claim 1, wherein said inositol is myoinositol.

### Claim 5 (depends on 1)

The method of claim 1, wherein said inositol is a combination of myoinositol and at least one isomer of inositol other than myoinositol.

### Claim 6 (depends on 5)

The method of claim 5, wherein said method comprises administering said myoinositol and said at least one isomer of inositol other than myoinositol to said subject simultaneously or non-simultaneously.

### Claim 7 (depends on 6)

The method of claim 6, wherein said method comprises administering said myoinositol and said at least one isomer of inositol other than myoinositol to said subject simultaneously, and wherein said myoinositol and said at least one isomer of inositol other than myoinositol are present in a composition comprising said myoinositol and said at least one isomer of inositol other than myoinositol.

### Claim 8 (depends on 7)

The method of claim 7, wherein said composition is a pharmaceutical composition additionally comprising at least one pharmaceutically acceptable ingredient.

### Claim 9 (depends on 5)

The method of claim 5, wherein said at least one isomer of inositol other than myoinositol comprises D-chiroinositol.

### Claim 10 (depends on 9)

The method of claim 9, wherein said method comprises administering myoinositol and D-chiroinositol to said subject in a respective weight ratio of about 10:1 to about 100:1, about 20:1 to about 80:1, about 30:1 to about 60:1, about 35:1 to about 50:1, about 40:1 or 40:1.

### Claim 11 (depends on 1)

The method of claim 1, wherein said method comprises administering to the subject
about 500-4000 mg myoinositol;
about 1000-2000 mg myoinositol;
about 2000 mg myoinositol;
about 600 mg myoinositol;
about 550 mg myoinositol;
about 550 mg myoinositol and about 13.8 mg D-chiroinositol; or
about 2000 mg myoinositol and about 50 mg D-chiroinositol.

### Claim 12 (depends on 9)

The method of claim 9, wherein said method comprises administering to the subject
about 5-100 mg D-chiroinositol;
about 10-50 mg D-chiroinositol;
about 50 mg D-chiroinositol; or
about 13.8 mg D-chiroinositol.

### Claim 13 (depends on 1)

The method of claim 1, wherein said method comprises administering to the subject a total of about 2050 mg total inositol in the form of a powder.

### Claim 14 (depends on 13)

The method of claim 13, wherein said about 2050 mg total inositol is constituted by about 2000 mg myoinositol and about 50 mg D-chiroinositol.

### Claim 15 (depends on 1)

The method of claim 1, wherein said method comprises administering to the subject a total of about 563.8 mg total inositol in the form of a soft gel capsule.

### Claim 16 (depends on 15)

The method of claim 15, wherein said about 563.8 mg total inositol is constituted by about 550 mg myoinositol and about 13.8 mg D-chiroinositol.
